121 related articles for article (PubMed ID: 33463239)
21. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
Benini S; Manara MC; Cerisano V; Perdichizzi S; Strammiello R; Serra M; Picci P; Scotlandi K
Int J Cancer; 2004 Jan; 108(3):358-66. PubMed ID: 14648701
[TBL] [Abstract][Full Text] [Related]
22. Three-dimensional poly-(ε-caprolactone) nanofibrous scaffolds directly promote the cardiomyocyte differentiation of murine-induced pluripotent stem cells through Wnt/β-catenin signaling.
Chen Y; Zeng D; Ding L; Li XL; Liu XT; Li WJ; Wei T; Yan S; Xie JH; Wei L; Zheng QS
BMC Cell Biol; 2015 Sep; 16():22. PubMed ID: 26335746
[TBL] [Abstract][Full Text] [Related]
23. Osteoinduction and proliferation of bone-marrow stromal cells in three-dimensional poly (ε-caprolactone)/ hydroxyapatite/collagen scaffolds.
Wang T; Yang X; Qi X; Jiang C
J Transl Med; 2015 May; 13():152. PubMed ID: 25952675
[TBL] [Abstract][Full Text] [Related]
24. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma.
Benini S; Zuntini M; Manara MC; Cohen P; Nicoletti G; Nanni P; Oh Y; Picci P; Scotlandi K
Int J Cancer; 2006 Sep; 119(5):1039-46. PubMed ID: 16570284
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
26. Ewing's sarcoma of bone tumor cells produces MCSF that stimulates monocyte proliferation in a novel mouse model of Ewing's sarcoma of bone.
Margulies BS; DeBoyace SD; Damron TA; Allen MJ
Bone; 2015 Oct; 79():121-30. PubMed ID: 26051470
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
Girnita L; Wang M; Xie Y; Nilsson G; Dricu A; Wejde J; Larsson O
Anticancer Drug Des; 2000 Feb; 15(1):67-72. PubMed ID: 10888037
[TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
[TBL] [Abstract][Full Text] [Related]
30. 3D Scaffolds with Different Stiffness but the Same Microstructure for Bone Tissue Engineering.
Chen G; Dong C; Yang L; Lv Y
ACS Appl Mater Interfaces; 2015 Jul; 7(29):15790-802. PubMed ID: 26151287
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapies in Ewing's sarcoma.
Scotlandi K
Adv Exp Med Biol; 2006; 587():13-22. PubMed ID: 17163152
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines.
Hofbauer S; Hamilton G; Theyer G; Wollmann K; Gabor F
Eur J Cancer; 1993; 29A(2):241-5. PubMed ID: 8380698
[TBL] [Abstract][Full Text] [Related]
33. Ornamenting 3D printed scaffolds with cell-laid extracellular matrix for bone tissue regeneration.
Pati F; Song TH; Rijal G; Jang J; Kim SW; Cho DW
Biomaterials; 2015 Jan; 37():230-41. PubMed ID: 25453953
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy in the management of osteosarcoma and Ewing's sarcoma.
Schuetze SM
J Natl Compr Canc Netw; 2007 Apr; 5(4):449-55. PubMed ID: 17442235
[TBL] [Abstract][Full Text] [Related]
36. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma).
Anderson P; Kopp L; Anderson N; Cornelius K; Herzog C; Hughes D; Huh W
Expert Opin Investig Drugs; 2008 Nov; 17(11):1703-15. PubMed ID: 18922107
[TBL] [Abstract][Full Text] [Related]
37. Enhanced osteogenic activity by MC3T3-E1 pre-osteoblasts on chemically surface-modified poly(ε-caprolactone) 3D-printed scaffolds compared to RGD immobilized scaffolds.
Zamani Y; Mohammadi J; Amoabediny G; Visscher DO; Helder MN; Zandieh-Doulabi B; Klein-Nulend J
Biomed Mater; 2018 Nov; 14(1):015008. PubMed ID: 30421722
[TBL] [Abstract][Full Text] [Related]
38. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
Benini S; Manara MC; Baldini N; Cerisano V; Massimo Serra ; Mercuri M; Lollini PL; Nanni P; Picci P; Scotlandi K
Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effect of scaffold composition and dynamic culturing environment in multilayered systems for bone tissue engineering.
Rodrigues MT; Martins A; Dias IR; Viegas CA; Neves NM; Gomes ME; Reis RL
J Tissue Eng Regen Med; 2012 Nov; 6(10):e24-30. PubMed ID: 22451140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
